Eli Lilly and Company (NYSE:LLY) is among the 12 Best Ethical Companies to Invest in 2025.
A close-up of a staff member counting pills in a pharmaceutical warehouse.
Eli Lilly and Company (NYSE:LLY) is experiencing a strong analyst sentiment amid its expanding role in cutting-edge treatments. On July 18, Leerink Partners maintained its ‘Buy’ rating on the company, citing growth potential through the GLP-1 receptor agonist (GLP-1RA) space. According to a new JAMA study, GLP-1RAs, like Eli Lilly’s ‘tirzepatide’ medication, not only improves blood sugar control but also reduces the risks of dementia, stroke, and death in adults with type 2 diabetes and obesity.
These research findings hold the potential to boost optimism ahead of results from Novo Nordisk’s Alzheimer’s trials. If the trial results are positive, it could benefit the company’s positioning in neurology. Having a strong foothold in both the incretin and Alzheimer’s markets, Eli Lilly and Company (NYSE:LLY) is poised for future growth.
On the same day, Jefferies also maintained a ‘Buy’ rating, setting its price target at $1,057. Eli Lilly and Company (NYSE:LLY) is trading at $805.43 at the time of writing.
Operating globally, Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals. It is one of the best ESG stocks.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Most Undervalued Cloud Stocks Under $10 According to Hedge Funds and 11 Best Mineral Stocks to Buy According to Hedge Funds.
Disclosure: None.